Health Reform in the Balance: What It Means for Biopharma
This article was originally published in RPM Report
Executive Summary
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach.
You may also be interested in...
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management
A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?